First-line Abraxane/Xeloda Doublet Viable in Metastatic Breast Cancer

Article

In a phase II,multicenter open-label study, Lee S.Schwartzberg, MD, et al evaluated 50patients with metastatic breast cancertreated with nab-paclitaxel (Abraxane)at 125 mg/m2 on days 1 and 8 andcapecitabine (Xeloda) at 825 mg/m2 bidon days 1–14 of a q3wk cycle (abstract1096).

MEMPHIS–In a phase II,multicenter open-label study, Lee S.Schwartzberg, MD, et al evaluated 50patients with metastatic breast cancertreated with nab-paclitaxel (Abraxane)at 125 mg/m2 on days 1 and 8 andcapecitabine (Xeloda) at 825 mg/m2 bidon days 1-14 of a q3wk cycle (abstract1096). The protocol was designed for 6cycles of therapy; some patients receivedup to 14 cycles (36 weeks). Data wereavailable on 38 patients at interim analysis.ORR was 53% (9% CR, 44% PR),and the 50% survival endpoint has notbeen reached. The only grade 4 toxicitywas hematologic (3 patients). Investigatorsnoted a 10% incidence each of neuropathyand hand-foot syndrome.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content